Modulation of IDO and PD-L1 expressing immune populations in the melanoma microenvironment with IO102-IO103 and nivolumab-relatlimab (SITC 2026) - Oct 2, 2026 - Abstract #866; Pres time: Nov 7, 2026; No abstract available
Clinical • Melanoma • Oncology • Solid Tumor • PD-L1
|
|
James Smithy; Matteo Serra; Andrea Moy; Xinjun Wang; Alexander Shoushtari; Parisa Momtaz; Monica Chen; Neeman Mohibullah; Michael Postow; Katherine Panageas; Ronglai Shen; Claire Thant
|